Genomed Spólka Akcyjna Past Earnings Performance
Past criteria checks 4/6
Genomed Spólka Akcyjna's earnings have been declining at an average annual rate of -9.2%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 3.4% per year. Genomed Spólka Akcyjna's return on equity is 6.4%, and it has net margins of 2.7%.
Key information
-9.2%
Earnings growth rate
-9.8%
EPS growth rate
Biotechs Industry Growth | 56.3% |
Revenue growth rate | 3.4% |
Return on equity | 6.4% |
Net Margin | 2.7% |
Next Earnings Update | 13 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Genomed Spólka Akcyjna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 22 | 1 | 12 | 0 |
31 Mar 24 | 22 | 1 | 11 | 0 |
31 Dec 23 | 22 | 1 | 11 | 0 |
30 Sep 23 | 21 | 0 | 11 | 0 |
30 Jun 23 | 21 | 0 | 11 | 0 |
31 Mar 23 | 21 | 0 | 11 | 0 |
31 Dec 22 | 20 | 0 | 10 | 0 |
30 Sep 22 | 20 | 1 | 10 | 0 |
30 Jun 22 | 20 | 1 | 11 | 0 |
31 Mar 22 | 20 | 2 | 10 | 0 |
31 Dec 21 | 20 | 1 | 10 | 0 |
30 Sep 21 | 20 | 1 | 10 | 0 |
30 Jun 21 | 20 | 1 | 10 | 0 |
31 Mar 21 | 19 | 0 | 10 | 0 |
31 Dec 20 | 19 | 0 | 10 | 0 |
30 Sep 20 | 19 | 0 | 10 | 0 |
30 Jun 20 | 19 | 1 | 10 | 0 |
31 Mar 20 | 20 | 1 | 11 | 0 |
31 Dec 19 | 20 | 1 | 11 | 0 |
30 Sep 19 | 19 | 1 | 11 | 0 |
30 Jun 19 | 19 | 1 | 11 | 0 |
31 Mar 19 | 18 | 1 | 10 | 0 |
31 Dec 18 | 19 | 1 | 10 | 0 |
30 Sep 18 | 18 | 2 | 9 | 0 |
30 Jun 18 | 17 | 2 | 8 | 0 |
31 Mar 18 | 17 | 2 | 8 | 0 |
31 Dec 17 | 16 | 2 | 8 | 0 |
30 Sep 17 | 16 | 1 | 9 | 0 |
30 Jun 17 | 16 | 1 | 9 | 0 |
31 Mar 17 | 15 | 0 | 9 | 0 |
31 Dec 16 | 14 | 0 | 9 | 0 |
30 Sep 16 | 14 | 1 | 8 | 0 |
30 Jun 16 | 12 | 1 | 7 | 0 |
31 Mar 16 | 11 | 0 | 7 | 0 |
31 Dec 15 | 10 | 0 | 7 | 0 |
30 Sep 15 | 9 | 0 | 7 | 0 |
30 Jun 15 | 8 | 0 | 7 | 0 |
31 Mar 15 | 8 | 0 | 6 | 0 |
31 Dec 14 | 7 | 0 | 6 | 0 |
30 Sep 14 | 6 | 0 | 6 | 0 |
30 Jun 14 | 6 | 0 | 5 | 0 |
31 Mar 14 | 5 | 0 | 5 | 0 |
31 Dec 13 | 5 | 0 | 4 | 0 |
30 Sep 13 | 5 | 0 | 4 | 0 |
Quality Earnings: GEN has high quality earnings.
Growing Profit Margin: GEN's current net profit margins (2.7%) are higher than last year (1.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GEN's earnings have declined by 9.2% per year over the past 5 years.
Accelerating Growth: GEN's earnings growth over the past year (113.5%) exceeds its 5-year average (-9.2% per year).
Earnings vs Industry: GEN earnings growth over the past year (113.5%) exceeded the Biotechs industry -0.08%.
Return on Equity
High ROE: GEN's Return on Equity (6.4%) is considered low.